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Case Presentation

A 37-year-old African American male presented to the hospital
complaining of high fevers over the past two weeks associated
with severe posterior headache. He described having had a very
poor appetite recently, but denied any cough, abdominal pain,
diarrhea, or urinary symptoms. He did not recall sustaining
any head trauma. He did relate, however, that he had recently
returned from a three-month trip to Kenya ~1 month prior to
this presentation. He had no past medical history and was not
on any medications. He did not use IV drugs. Physical exam
confirmed a fever of 102.1o F though normotensive 110/82 mm
Hg and a resting heart rate 110 bpm. The complete physical
exam including cardiopulmonary, abdominal, and neurological
examination was normal. Laboratory analysis was unrevealing.
A head CT performed prior to the lumbar puncture also failed
to reveal any abnormalities. However, given the patient’s recent
travel history, the team empirically began him on antimalarial
treatment against P. falciparum (quinine sulfate 10 mg/kg every
eight hours and doxycycline 100mg po bid) while awaiting
confirmatory histologic diagnosis. The next day malaria was
confirmed when the results of the thick and thin smear were
positive for plasmodium with a viral level greater than 1%.
During his hospitalization he was noted to have recurrent fevers
occurring almost every other day. His clinical status remained
stable without any alterations of his laboratory data. He was
discharged to complete his course of oral medications.

Discussion

~300,000 to 500,000 new cases of malaria occur worldwide with
700,000 to 2.7 million deaths estimated worldwide. ~30,000
travelers from industrialized nations countries reportedly
contract malaria. Infection occurs through the transmission of
an infected Anopheles mosquito. Human malaria is caused by
four species of Plasmodia: P. falciparum, P. vivax, P. ovale, and
P. malariae. Each of the four species causes clinical disease by
resulting ultimately in hemolysis. P. falciparum has the ability
to invade red blood cells of all ages and it is associated with
the highest risk and rate of morbidity and mortality. Relapsing
fevers remain the clinical hallmark of malaria. Anemia,
thrombocytopenia, splenomegaly, hepatomegaly and jaundice
can develop, and splenic rupture can occasionally occur as well.
Altered consciousness, oliguira, hypoglycemia, and organ failure
are characteristics of severe P. falciparum infection.

serologic markers analysis. Thick and thin blood smears should
be examined at least every 12 hours to monitor the efficacy
of therapy until the parasitemia is below 1 %. Smears should
also be obtained at 3, 7, and 28 days to rule out recurrence or
incomplete clearance of parasitemia.
There are several medications available for the treatment of
malaria including quinoline derivatives, antifolates, artemisinin
derivatives, and antimicrobials. P. ovale and P. malariae
are universally sensitive to chloroquine. Several strains of
chloroquine-resistent P. vivax have been reported. The Centers
for Disease Control (CDC) recommend treatment of chloroquine
sensitive species of malaria with chloroquine followed by a
course of primaquine. Resistant P. vivax can be treated with
mefloquine or quinine sulfate plus doxycycline. Clinically, it is
very important that one distinguish between P. falciparum and
the other species of malaria, as P. falciparum is largely resistant
to chloroquine and this discernment will ultimately affect the
final drug cocktail prescribed. Failure to identify P. falciparum
could otherwise result in inadequate and delayed treatment with
the wrong medications. Fortunately, many treatment regimens
exist for the treatment of P. falciparum. The most commonly
recommend regimen is quinine sulfate with pyrimethaminesulfadoxine or doxycycline.
When advising patients on foreign travel, physicians should be
aware of resistance patterns of malaria based upon geographic
locale. This will tailor the choice of malarial prophylaxis unique
to the area. Prevention is paramount for travelers to endemic
areas and many resources through the CDC exist to provide
education to both clinicians and patients on anti-malarial
drugs.
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The diagnosis should be suspected in patients with recurrent
fevers that travel to endemic areas. The gold standard of
diagnosis is through examination of thick and thin smears with
light microscopy. Parasite levels are measurable and levels can
correlate with both type of species as well as portend overall
morbidity. Microscopy is regularly employed to assess a
patient’s response to treatment. Other diagnostic tests available
include antigen detection, fluorescent microscopy, PCR and
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